Basics Repligen Corporation Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. The company offers its products to life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. IPO Date: March 26, 1990 Sector: Healthcare Industry: Life Sciences Tools and Services Market Cap: $6.88B Activated in VL: True Average Daily Range Avg Daily Range: $1.16 | 2.15% Avg Daily Range (30 D): $2.68 | 2.04% Avg Daily Range (90 D): $3.42 | 2.50% Institutional Daily Volume Avg Daily Volume: .29M Avg Daily Volume (30 D): .71M Avg Daily Volume (90 D): .66M Trade Size Avg Trade Size (Sh.): 73 Avg Trade Size (Sh.) (30 D): 43 Avg Trade Size (Sh.) (90 D): 42 Institutional Trades Total Inst.Trades: 5,572 Avg Inst. Trade: $4.89M Avg Inst. Trade (30 D): $6.19M Avg Inst. Trade (90 D): $6.8M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $6.86M Avg Closing Trade (30 D): $11.59M Avg Closing Trade (90 D): $11.47M Avg Closing Volume: 59.17K         News Feb 20, 2025 @ 4:25 PM Repligen's Q4 Slightly Tops Expectations Source: Jesterai Jan 9, 2025 @ 12:30 AM Chromatography System Market to Reach US$ 2.62 Bil... Source: Fact.Mr Dec 16, 2024 @ 1:11 PM BioLife Solutions Appoints Tony J. Hunt to its Boa... Source: Prnewswire Dec 12, 2024 @ 12:30 PM Repligen Announces Publication of the Companyâ€... Source: N/A Jun 26, 2024 @ 12:44 PM This Robinhood Analyst Turns Bullish; Here Are Top... Source: Avi Kapoor Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.46 $.1 $-.61 Diluted EPS $-.46 $.1 $-.61 Revenue $ 645.66M $ 169.17M $ 167.55M Gross Profit $ 283.85M $ 90.76M $ 38.84M Net Income / Loss $ -25.37M $ 5.83M $ -33.87M Operating Income / Loss $ -36.27M $ 6.58M $ -36.5M Cost of Revenue $ 361.82M $ 78.42M $ 128.71M Net Cash Flow $ -85.4M $ -64.13M $ -24.14M PE Ratio